Indications for: TACLONEX OINTMENT
Adults and Children:
<12yrs: not established. Apply to affected areas once daily for up to 4 weeks; discontinue when control is achieved. 12–17yrs: max 60g/wk. ≥18yrs: max 100g/wk. Limit treatment area to max 30% body surface area. Do not occlude.
TACLONEX OINTMENT Warnings/Precautions:
Avoid use near eyes, on face, groin, or axillae, or if atrophy is present at treatment site. Discontinue if hypercalcemia or hypercalciuria develop; may resume once calcium metabolism has normalized. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, hyperglycemia, or irritation occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Avoid sun, UV light (eg, phototherapy). Allergic contact dermatitis. Pregnancy. Nursing mothers.
TACLONEX OINTMENT Classification:
Vit. D3 derivative + topical steroid.
TACLONEX OINTMENT Interactions:
Systemic absorption potentiated by other corticosteroids.
Oint: pruritus, scaly rash. Susp: folliculitis, burning sensation of skin.
Generic Drug Availability:
Oint—60g, 100g; Susp—60g, 2x60g